nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—ALB—Vismodegib—skin cancer	0.189	0.284	CbGbCtD
Gliclazide—ALB—Vemurafenib—skin cancer	0.149	0.224	CbGbCtD
Gliclazide—CYP2C19—Vismodegib—skin cancer	0.123	0.184	CbGbCtD
Gliclazide—CYP2C9—Vismodegib—skin cancer	0.102	0.153	CbGbCtD
Gliclazide—ALB—Fluorouracil—skin cancer	0.0672	0.101	CbGbCtD
Gliclazide—CYP2C9—Fluorouracil—skin cancer	0.0362	0.0543	CbGbCtD
Gliclazide—ABCC8—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.00181	0.0627	CbGpPWpGaD
Gliclazide—KCNJ11—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.00175	0.0608	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR1 specific signals—RASA1—skin cancer	0.00132	0.0459	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.00126	0.0437	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—RASA1—skin cancer	0.00116	0.0404	CbGpPWpGaD
Gliclazide—VEGFA—Beta1 integrin cell surface interactions—CSPG4—skin cancer	0.00101	0.0352	CbGpPWpGaD
Gliclazide—VEGFA—Heart Development—SHH—skin cancer	0.000954	0.0331	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—SHH—skin cancer	0.00089	0.0309	CbGpPWpGaD
Gliclazide—VEGFA—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—skin cancer	0.000746	0.0259	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—PTCH1—skin cancer	0.00067	0.0232	CbGpPWpGaD
Gliclazide—VEGFA—S1P1 pathway—PTGS2—skin cancer	0.00065	0.0226	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—CDK4—skin cancer	0.000615	0.0213	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—XRCC3—skin cancer	0.000587	0.0204	CbGpPWpGaD
Gliclazide—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.000582	0.0202	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—BRAF—skin cancer	0.000544	0.0189	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—RASA1—skin cancer	0.000516	0.0179	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—CDKN2A—skin cancer	0.00047	0.0163	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—RASA1—skin cancer	0.000466	0.0161	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—RASA1—skin cancer	0.000439	0.0152	CbGpPWpGaD
Gliclazide—Pharyngitis—Temozolomide—skin cancer	0.000388	0.00127	CcSEcCtD
Gliclazide—Chills—Dactinomycin—skin cancer	0.000387	0.00127	CcSEcCtD
Gliclazide—Oedema peripheral—Temozolomide—skin cancer	0.000385	0.00126	CcSEcCtD
Gliclazide—Cardiac failure—Docetaxel—skin cancer	0.000385	0.00126	CcSEcCtD
Gliclazide—Pruritus—Vemurafenib—skin cancer	0.000384	0.00126	CcSEcCtD
Gliclazide—Feeling abnormal—Imiquimod—skin cancer	0.000381	0.00125	CcSEcCtD
Gliclazide—Gastrointestinal pain—Imiquimod—skin cancer	0.000379	0.00124	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—MSH2—skin cancer	0.000378	0.0131	CbGpPWpGaD
Gliclazide—Epistaxis—Fluorouracil—skin cancer	0.000378	0.00124	CcSEcCtD
Gliclazide—Hyponatraemia—Docetaxel—skin cancer	0.000377	0.00124	CcSEcCtD
Gliclazide—Visual impairment—Temozolomide—skin cancer	0.000376	0.00123	CcSEcCtD
Gliclazide—Sinusitis—Fluorouracil—skin cancer	0.000376	0.00123	CcSEcCtD
Gliclazide—Erythema—Dactinomycin—skin cancer	0.000376	0.00123	CcSEcCtD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—TERT—skin cancer	0.000375	0.013	CbGpPWpGaD
Gliclazide—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000375	0.00123	CcSEcCtD
Gliclazide—Pain in extremity—Docetaxel—skin cancer	0.000375	0.00123	CcSEcCtD
Gliclazide—Agranulocytosis—Fluorouracil—skin cancer	0.000374	0.00123	CcSEcCtD
Gliclazide—Ill-defined disorder—Bleomycin—skin cancer	0.000374	0.00123	CcSEcCtD
Gliclazide—Anaemia—Bleomycin—skin cancer	0.000372	0.00122	CcSEcCtD
Gliclazide—Diarrhoea—Vemurafenib—skin cancer	0.000371	0.00122	CcSEcCtD
Gliclazide—Erythema multiforme—Temozolomide—skin cancer	0.000369	0.00121	CcSEcCtD
Gliclazide—Urticaria—Imiquimod—skin cancer	0.000368	0.00121	CcSEcCtD
Gliclazide—Abdominal pain—Imiquimod—skin cancer	0.000366	0.0012	CcSEcCtD
Gliclazide—Body temperature increased—Imiquimod—skin cancer	0.000366	0.0012	CcSEcCtD
Gliclazide—Eye disorder—Temozolomide—skin cancer	0.000365	0.0012	CcSEcCtD
Gliclazide—Tinnitus—Temozolomide—skin cancer	0.000364	0.00119	CcSEcCtD
Gliclazide—Malaise—Bleomycin—skin cancer	0.000363	0.00119	CcSEcCtD
Gliclazide—Flushing—Temozolomide—skin cancer	0.000362	0.00119	CcSEcCtD
Gliclazide—Leukopenia—Bleomycin—skin cancer	0.000361	0.00118	CcSEcCtD
Gliclazide—Rhinitis—Fluorouracil—skin cancer	0.000361	0.00118	CcSEcCtD
Gliclazide—Dizziness—Vemurafenib—skin cancer	0.000359	0.00118	CcSEcCtD
Gliclazide—Hypoaesthesia—Fluorouracil—skin cancer	0.000358	0.00117	CcSEcCtD
Gliclazide—Pharyngitis—Fluorouracil—skin cancer	0.000357	0.00117	CcSEcCtD
Gliclazide—Cough—Bleomycin—skin cancer	0.000352	0.00115	CcSEcCtD
Gliclazide—Chills—Temozolomide—skin cancer	0.00035	0.00115	CcSEcCtD
Gliclazide—Ill-defined disorder—Dactinomycin—skin cancer	0.000349	0.00114	CcSEcCtD
Gliclazide—Anaemia—Dactinomycin—skin cancer	0.000347	0.00114	CcSEcCtD
Gliclazide—Vomiting—Vemurafenib—skin cancer	0.000345	0.00113	CcSEcCtD
Gliclazide—Dry skin—Docetaxel—skin cancer	0.000344	0.00113	CcSEcCtD
Gliclazide—Chest pain—Bleomycin—skin cancer	0.000343	0.00113	CcSEcCtD
Gliclazide—Myalgia—Bleomycin—skin cancer	0.000343	0.00113	CcSEcCtD
Gliclazide—Rash—Vemurafenib—skin cancer	0.000342	0.00112	CcSEcCtD
Gliclazide—Mental disorder—Temozolomide—skin cancer	0.000342	0.00112	CcSEcCtD
Gliclazide—Dermatitis—Vemurafenib—skin cancer	0.000342	0.00112	CcSEcCtD
Gliclazide—Hypersensitivity—Imiquimod—skin cancer	0.000341	0.00112	CcSEcCtD
Gliclazide—Headache—Vemurafenib—skin cancer	0.00034	0.00112	CcSEcCtD
Gliclazide—Erythema—Temozolomide—skin cancer	0.00034	0.00112	CcSEcCtD
Gliclazide—Malnutrition—Temozolomide—skin cancer	0.00034	0.00112	CcSEcCtD
Gliclazide—Discomfort—Bleomycin—skin cancer	0.000339	0.00111	CcSEcCtD
Gliclazide—Malaise—Dactinomycin—skin cancer	0.000339	0.00111	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000338	0.00111	CcSEcCtD
Gliclazide—Leukopenia—Dactinomycin—skin cancer	0.000336	0.0011	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—SCN10A—skin cancer	0.000334	0.0116	CbGpPWpGaD
Gliclazide—Asthenia—Imiquimod—skin cancer	0.000332	0.00109	CcSEcCtD
Gliclazide—Confusional state—Bleomycin—skin cancer	0.000332	0.00109	CcSEcCtD
Gliclazide—Back pain—Temozolomide—skin cancer	0.000329	0.00108	CcSEcCtD
Gliclazide—Pruritus—Imiquimod—skin cancer	0.000328	0.00107	CcSEcCtD
Gliclazide—Infection—Bleomycin—skin cancer	0.000327	0.00107	CcSEcCtD
Gliclazide—Nausea—Vemurafenib—skin cancer	0.000322	0.00106	CcSEcCtD
Gliclazide—Thrombocytopenia—Bleomycin—skin cancer	0.000322	0.00106	CcSEcCtD
Gliclazide—Arrhythmia—Fluorouracil—skin cancer	0.000321	0.00105	CcSEcCtD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	0.000321	0.0111	CbGpPWpGaD
Gliclazide—Myalgia—Dactinomycin—skin cancer	0.00032	0.00105	CcSEcCtD
Gliclazide—Tremor—Temozolomide—skin cancer	0.000318	0.00105	CcSEcCtD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—NRAS—skin cancer	0.000318	0.011	CbGpPWpGaD
Gliclazide—Diarrhoea—Imiquimod—skin cancer	0.000317	0.00104	CcSEcCtD
Gliclazide—Discomfort—Dactinomycin—skin cancer	0.000316	0.00104	CcSEcCtD
Gliclazide—Angina pectoris—Docetaxel—skin cancer	0.000316	0.00104	CcSEcCtD
Gliclazide—Ill-defined disorder—Temozolomide—skin cancer	0.000315	0.00103	CcSEcCtD
Gliclazide—Anaemia—Temozolomide—skin cancer	0.000314	0.00103	CcSEcCtD
Gliclazide—Erythema—Fluorouracil—skin cancer	0.000313	0.00103	CcSEcCtD
Gliclazide—Agitation—Temozolomide—skin cancer	0.000312	0.00103	CcSEcCtD
Gliclazide—Angioedema—Temozolomide—skin cancer	0.000311	0.00102	CcSEcCtD
Gliclazide—Pancytopenia—Docetaxel—skin cancer	0.000308	0.00101	CcSEcCtD
Gliclazide—Hypotension—Bleomycin—skin cancer	0.000307	0.00101	CcSEcCtD
Gliclazide—Malaise—Temozolomide—skin cancer	0.000307	0.00101	CcSEcCtD
Gliclazide—Dizziness—Imiquimod—skin cancer	0.000306	0.001	CcSEcCtD
Gliclazide—Infection—Dactinomycin—skin cancer	0.000305	0.001	CcSEcCtD
Gliclazide—Leukopenia—Temozolomide—skin cancer	0.000304	0.000998	CcSEcCtD
Gliclazide—Palpitations—Temozolomide—skin cancer	0.0003	0.000986	CcSEcCtD
Gliclazide—Thrombocytopenia—Dactinomycin—skin cancer	0.0003	0.000985	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Bleomycin—skin cancer	0.0003	0.000983	CcSEcCtD
Gliclazide—Cough—Temozolomide—skin cancer	0.000297	0.000973	CcSEcCtD
Gliclazide—Paraesthesia—Bleomycin—skin cancer	0.000295	0.000969	CcSEcCtD
Gliclazide—Weight increased—Docetaxel—skin cancer	0.000295	0.000969	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000295	0.0102	CbGpPWpGaD
Gliclazide—Convulsion—Temozolomide—skin cancer	0.000294	0.000966	CcSEcCtD
Gliclazide—Vomiting—Imiquimod—skin cancer	0.000294	0.000966	CcSEcCtD
Gliclazide—Hypertension—Temozolomide—skin cancer	0.000293	0.000963	CcSEcCtD
Gliclazide—Dyspnoea—Bleomycin—skin cancer	0.000293	0.000962	CcSEcCtD
Gliclazide—Rash—Imiquimod—skin cancer	0.000292	0.000958	CcSEcCtD
Gliclazide—Dermatitis—Imiquimod—skin cancer	0.000292	0.000957	CcSEcCtD
Gliclazide—Pneumonia—Docetaxel—skin cancer	0.000291	0.000955	CcSEcCtD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—skin cancer	0.00029	0.0101	CbGpPWpGaD
Gliclazide—Headache—Imiquimod—skin cancer	0.00029	0.000952	CcSEcCtD
Gliclazide—Anaemia—Fluorouracil—skin cancer	0.000289	0.00095	CcSEcCtD
Gliclazide—Arthralgia—Temozolomide—skin cancer	0.000289	0.00095	CcSEcCtD
Gliclazide—Myalgia—Temozolomide—skin cancer	0.000289	0.00095	CcSEcCtD
Gliclazide—Anxiety—Temozolomide—skin cancer	0.000288	0.000946	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000287	0.000943	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000287	0.000941	CcSEcCtD
Gliclazide—Discomfort—Temozolomide—skin cancer	0.000286	0.000938	CcSEcCtD
Gliclazide—Acute coronary syndrome—Docetaxel—skin cancer	0.000285	0.000936	CcSEcCtD
Gliclazide—Renal failure—Docetaxel—skin cancer	0.000284	0.000933	CcSEcCtD
Gliclazide—Neuropathy peripheral—Docetaxel—skin cancer	0.000284	0.00093	CcSEcCtD
Gliclazide—Myocardial infarction—Docetaxel—skin cancer	0.000284	0.00093	CcSEcCtD
Gliclazide—Dry mouth—Temozolomide—skin cancer	0.000283	0.000929	CcSEcCtD
Gliclazide—Jaundice—Docetaxel—skin cancer	0.000282	0.000925	CcSEcCtD
Gliclazide—Pain—Bleomycin—skin cancer	0.000281	0.000923	CcSEcCtD
Gliclazide—Conjunctivitis—Docetaxel—skin cancer	0.000281	0.000923	CcSEcCtD
Gliclazide—Leukopenia—Fluorouracil—skin cancer	0.00028	0.00092	CcSEcCtD
Gliclazide—Confusional state—Temozolomide—skin cancer	0.00028	0.000918	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000279	0.000917	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000279	0.00969	CbGpPWpGaD
Gliclazide—Infection—Temozolomide—skin cancer	0.000276	0.000904	CcSEcCtD
Gliclazide—Nausea—Imiquimod—skin cancer	0.000275	0.000902	CcSEcCtD
Gliclazide—Hepatobiliary disease—Docetaxel—skin cancer	0.000274	0.000898	CcSEcCtD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—KRAS—skin cancer	0.000273	0.00948	CbGpPWpGaD
Gliclazide—Epistaxis—Docetaxel—skin cancer	0.000273	0.000895	CcSEcCtD
Gliclazide—Nervous system disorder—Temozolomide—skin cancer	0.000272	0.000893	CcSEcCtD
Gliclazide—Thrombocytopenia—Temozolomide—skin cancer	0.000272	0.000891	CcSEcCtD
Gliclazide—Convulsion—Fluorouracil—skin cancer	0.000271	0.00089	CcSEcCtD
Gliclazide—Feeling abnormal—Bleomycin—skin cancer	0.000271	0.000889	CcSEcCtD
Gliclazide—Agranulocytosis—Docetaxel—skin cancer	0.00027	0.000886	CcSEcCtD
Gliclazide—Skin disorder—Temozolomide—skin cancer	0.000269	0.000884	CcSEcCtD
Gliclazide—Hyperhidrosis—Temozolomide—skin cancer	0.000268	0.00088	CcSEcCtD
Gliclazide—Chest pain—Fluorouracil—skin cancer	0.000267	0.000875	CcSEcCtD
Gliclazide—Myalgia—Fluorouracil—skin cancer	0.000267	0.000875	CcSEcCtD
Gliclazide—Fatigue—Dactinomycin—skin cancer	0.000264	0.000868	CcSEcCtD
Gliclazide—Discomfort—Fluorouracil—skin cancer	0.000263	0.000864	CcSEcCtD
Gliclazide—Pain—Dactinomycin—skin cancer	0.000262	0.000861	CcSEcCtD
Gliclazide—VEGFA—Bladder Cancer—TP53—skin cancer	0.000262	0.00908	CbGpPWpGaD
Gliclazide—Urticaria—Bleomycin—skin cancer	0.000261	0.000857	CcSEcCtD
Gliclazide—Rhinitis—Docetaxel—skin cancer	0.00026	0.000854	CcSEcCtD
Gliclazide—Body temperature increased—Bleomycin—skin cancer	0.00026	0.000853	CcSEcCtD
Gliclazide—Hepatitis—Docetaxel—skin cancer	0.00026	0.000852	CcSEcCtD
Gliclazide—Hypoaesthesia—Docetaxel—skin cancer	0.000258	0.000848	CcSEcCtD
Gliclazide—Confusional state—Fluorouracil—skin cancer	0.000258	0.000846	CcSEcCtD
Gliclazide—Pharyngitis—Docetaxel—skin cancer	0.000258	0.000846	CcSEcCtD
Gliclazide—Oedema peripheral—Docetaxel—skin cancer	0.000256	0.000839	CcSEcCtD
Gliclazide—Infection—Fluorouracil—skin cancer	0.000254	0.000833	CcSEcCtD
Gliclazide—Feeling abnormal—Dactinomycin—skin cancer	0.000253	0.000829	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000253	0.000829	CcSEcCtD
Gliclazide—Insomnia—Temozolomide—skin cancer	0.000251	0.000823	CcSEcCtD
Gliclazide—Gastrointestinal pain—Dactinomycin—skin cancer	0.000251	0.000823	CcSEcCtD
Gliclazide—Nervous system disorder—Fluorouracil—skin cancer	0.000251	0.000823	CcSEcCtD
Gliclazide—Thrombocytopenia—Fluorouracil—skin cancer	0.00025	0.000821	CcSEcCtD
Gliclazide—Visual impairment—Docetaxel—skin cancer	0.00025	0.000821	CcSEcCtD
Gliclazide—VEGFA—Bladder Cancer—HRAS—skin cancer	0.00025	0.00868	CbGpPWpGaD
Gliclazide—Tachycardia—Fluorouracil—skin cancer	0.000249	0.000819	CcSEcCtD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—NRAS—skin cancer	0.000249	0.00865	CbGpPWpGaD
Gliclazide—Paraesthesia—Temozolomide—skin cancer	0.000249	0.000817	CcSEcCtD
Gliclazide—Dyspnoea—Temozolomide—skin cancer	0.000247	0.000812	CcSEcCtD
Gliclazide—Somnolence—Temozolomide—skin cancer	0.000247	0.000809	CcSEcCtD
Gliclazide—Erythema multiforme—Docetaxel—skin cancer	0.000246	0.000806	CcSEcCtD
Gliclazide—Dyspepsia—Temozolomide—skin cancer	0.000244	0.000801	CcSEcCtD
Gliclazide—Eye disorder—Docetaxel—skin cancer	0.000243	0.000796	CcSEcCtD
Gliclazide—Abdominal pain—Dactinomycin—skin cancer	0.000242	0.000796	CcSEcCtD
Gliclazide—Body temperature increased—Dactinomycin—skin cancer	0.000242	0.000796	CcSEcCtD
Gliclazide—Hypersensitivity—Bleomycin—skin cancer	0.000242	0.000795	CcSEcCtD
Gliclazide—Flushing—Docetaxel—skin cancer	0.000241	0.000791	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Temozolomide—skin cancer	0.000239	0.000786	CcSEcCtD
Gliclazide—Fatigue—Temozolomide—skin cancer	0.000239	0.000785	CcSEcCtD
Gliclazide—Hypotension—Fluorouracil—skin cancer	0.000239	0.000784	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—SCN10A—skin cancer	0.000238	0.00827	CbGpPWpGaD
Gliclazide—Constipation—Temozolomide—skin cancer	0.000237	0.000778	CcSEcCtD
Gliclazide—Pain—Temozolomide—skin cancer	0.000237	0.000778	CcSEcCtD
Gliclazide—Asthenia—Bleomycin—skin cancer	0.000236	0.000774	CcSEcCtD
Gliclazide—Chills—Docetaxel—skin cancer	0.000233	0.000765	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000233	0.000764	CcSEcCtD
Gliclazide—Pruritus—Bleomycin—skin cancer	0.000233	0.000763	CcSEcCtD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—HRAS—skin cancer	0.000232	0.00806	CbGpPWpGaD
Gliclazide—Arrhythmia—Docetaxel—skin cancer	0.000232	0.000761	CcSEcCtD
Gliclazide—Insomnia—Fluorouracil—skin cancer	0.000231	0.000759	CcSEcCtD
Gliclazide—Paraesthesia—Fluorouracil—skin cancer	0.00023	0.000753	CcSEcCtD
Gliclazide—Feeling abnormal—Temozolomide—skin cancer	0.000229	0.00075	CcSEcCtD
Gliclazide—Dyspnoea—Fluorouracil—skin cancer	0.000228	0.000748	CcSEcCtD
Gliclazide—Mental disorder—Docetaxel—skin cancer	0.000227	0.000747	CcSEcCtD
Gliclazide—Somnolence—Fluorouracil—skin cancer	0.000227	0.000746	CcSEcCtD
Gliclazide—Gastrointestinal pain—Temozolomide—skin cancer	0.000227	0.000744	CcSEcCtD
Gliclazide—Erythema—Docetaxel—skin cancer	0.000226	0.000742	CcSEcCtD
Gliclazide—Malnutrition—Docetaxel—skin cancer	0.000226	0.000742	CcSEcCtD
Gliclazide—Hypersensitivity—Dactinomycin—skin cancer	0.000226	0.000742	CcSEcCtD
Gliclazide—Dyspepsia—Fluorouracil—skin cancer	0.000225	0.000738	CcSEcCtD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—IL6—skin cancer	0.000222	0.00772	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000222	0.00769	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000221	0.000724	CcSEcCtD
Gliclazide—Urticaria—Temozolomide—skin cancer	0.00022	0.000723	CcSEcCtD
Gliclazide—Asthenia—Dactinomycin—skin cancer	0.00022	0.000722	CcSEcCtD
Gliclazide—Abdominal pain—Temozolomide—skin cancer	0.000219	0.00072	CcSEcCtD
Gliclazide—Body temperature increased—Temozolomide—skin cancer	0.000219	0.00072	CcSEcCtD
Gliclazide—Back pain—Docetaxel—skin cancer	0.000219	0.000717	CcSEcCtD
Gliclazide—Pain—Fluorouracil—skin cancer	0.000219	0.000717	CcSEcCtD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—KRAS—skin cancer	0.000215	0.00745	CbGpPWpGaD
Gliclazide—Feeling abnormal—Fluorouracil—skin cancer	0.000211	0.000691	CcSEcCtD
Gliclazide—Diarrhoea—Dactinomycin—skin cancer	0.00021	0.000689	CcSEcCtD
Gliclazide—Vomiting—Bleomycin—skin cancer	0.000209	0.000686	CcSEcCtD
Gliclazide—Anaemia—Docetaxel—skin cancer	0.000209	0.000686	CcSEcCtD
Gliclazide—Rash—Bleomycin—skin cancer	0.000207	0.00068	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—NRAS—skin cancer	0.000207	0.00719	CbGpPWpGaD
Gliclazide—Dermatitis—Bleomycin—skin cancer	0.000207	0.00068	CcSEcCtD
Gliclazide—Hypersensitivity—Temozolomide—skin cancer	0.000204	0.000671	CcSEcCtD
Gliclazide—Urticaria—Fluorouracil—skin cancer	0.000203	0.000666	CcSEcCtD
Gliclazide—Leukopenia—Docetaxel—skin cancer	0.000202	0.000664	CcSEcCtD
Gliclazide—Body temperature increased—Fluorouracil—skin cancer	0.000202	0.000663	CcSEcCtD
Gliclazide—Palpitations—Docetaxel—skin cancer	0.0002	0.000655	CcSEcCtD
Gliclazide—Asthenia—Temozolomide—skin cancer	0.000199	0.000653	CcSEcCtD
Gliclazide—Loss of consciousness—Docetaxel—skin cancer	0.000199	0.000652	CcSEcCtD
Gliclazide—Cough—Docetaxel—skin cancer	0.000197	0.000647	CcSEcCtD
Gliclazide—Pruritus—Temozolomide—skin cancer	0.000196	0.000644	CcSEcCtD
Gliclazide—Convulsion—Docetaxel—skin cancer	0.000196	0.000643	CcSEcCtD
Gliclazide—Nausea—Bleomycin—skin cancer	0.000195	0.000641	CcSEcCtD
Gliclazide—Hypertension—Docetaxel—skin cancer	0.000195	0.00064	CcSEcCtD
Gliclazide—Vomiting—Dactinomycin—skin cancer	0.000195	0.00064	CcSEcCtD
Gliclazide—Rash—Dactinomycin—skin cancer	0.000193	0.000635	CcSEcCtD
Gliclazide—Arthralgia—Docetaxel—skin cancer	0.000192	0.000631	CcSEcCtD
Gliclazide—Myalgia—Docetaxel—skin cancer	0.000192	0.000631	CcSEcCtD
Gliclazide—Chest pain—Docetaxel—skin cancer	0.000192	0.000631	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—RASA1—skin cancer	0.000192	0.00666	CbGpPWpGaD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000191	0.000627	CcSEcCtD
Gliclazide—Diarrhoea—Temozolomide—skin cancer	0.00019	0.000623	CcSEcCtD
Gliclazide—Hypersensitivity—Fluorouracil—skin cancer	0.000188	0.000618	CcSEcCtD
Gliclazide—Dry mouth—Docetaxel—skin cancer	0.000188	0.000618	CcSEcCtD
Gliclazide—Confusional state—Docetaxel—skin cancer	0.000186	0.00061	CcSEcCtD
Gliclazide—Dizziness—Temozolomide—skin cancer	0.000183	0.000602	CcSEcCtD
Gliclazide—Infection—Docetaxel—skin cancer	0.000183	0.000601	CcSEcCtD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—HRAS—skin cancer	0.000182	0.00633	CbGpPWpGaD
Gliclazide—Nausea—Dactinomycin—skin cancer	0.000182	0.000598	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—RHOU—skin cancer	0.000182	0.00632	CbGpPWpGaD
Gliclazide—Nervous system disorder—Docetaxel—skin cancer	0.000181	0.000594	CcSEcCtD
Gliclazide—Pruritus—Fluorouracil—skin cancer	0.000181	0.000593	CcSEcCtD
Gliclazide—Thrombocytopenia—Docetaxel—skin cancer	0.000181	0.000593	CcSEcCtD
Gliclazide—Tachycardia—Docetaxel—skin cancer	0.00018	0.000591	CcSEcCtD
Gliclazide—Skin disorder—Docetaxel—skin cancer	0.000179	0.000588	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—KRAS—skin cancer	0.000178	0.00619	CbGpPWpGaD
Gliclazide—Vomiting—Temozolomide—skin cancer	0.000176	0.000579	CcSEcCtD
Gliclazide—Rash—Temozolomide—skin cancer	0.000175	0.000574	CcSEcCtD
Gliclazide—Diarrhoea—Fluorouracil—skin cancer	0.000175	0.000574	CcSEcCtD
Gliclazide—Dermatitis—Temozolomide—skin cancer	0.000175	0.000573	CcSEcCtD
Gliclazide—Headache—Temozolomide—skin cancer	0.000174	0.00057	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CDK4—skin cancer	0.000173	0.00601	CbGpPWpGaD
Gliclazide—Hypotension—Docetaxel—skin cancer	0.000172	0.000566	CcSEcCtD
Gliclazide—Dizziness—Fluorouracil—skin cancer	0.000169	0.000555	CcSEcCtD
Gliclazide—VEGFA—Differentiation Pathway—IL6—skin cancer	0.000169	0.00586	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000168	0.000552	CcSEcCtD
Gliclazide—Insomnia—Docetaxel—skin cancer	0.000167	0.000548	CcSEcCtD
Gliclazide—Paraesthesia—Docetaxel—skin cancer	0.000166	0.000544	CcSEcCtD
Gliclazide—Nausea—Temozolomide—skin cancer	0.000165	0.000541	CcSEcCtD
Gliclazide—Dyspnoea—Docetaxel—skin cancer	0.000164	0.00054	CcSEcCtD
Gliclazide—Somnolence—Docetaxel—skin cancer	0.000164	0.000538	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—KRAS—skin cancer	0.000163	0.00565	CbGpPWpGaD
Gliclazide—Vomiting—Fluorouracil—skin cancer	0.000163	0.000533	CcSEcCtD
Gliclazide—Dyspepsia—Docetaxel—skin cancer	0.000162	0.000533	CcSEcCtD
Gliclazide—Rash—Fluorouracil—skin cancer	0.000161	0.000529	CcSEcCtD
Gliclazide—Dermatitis—Fluorouracil—skin cancer	0.000161	0.000528	CcSEcCtD
Gliclazide—Headache—Fluorouracil—skin cancer	0.00016	0.000525	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Docetaxel—skin cancer	0.000159	0.000523	CcSEcCtD
Gliclazide—Fatigue—Docetaxel—skin cancer	0.000159	0.000522	CcSEcCtD
Gliclazide—Pain—Docetaxel—skin cancer	0.000158	0.000518	CcSEcCtD
Gliclazide—Constipation—Docetaxel—skin cancer	0.000158	0.000518	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—BRAF—skin cancer	0.000153	0.00532	CbGpPWpGaD
Gliclazide—Feeling abnormal—Docetaxel—skin cancer	0.000152	0.000499	CcSEcCtD
Gliclazide—Nausea—Fluorouracil—skin cancer	0.000152	0.000498	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—HRAS—skin cancer	0.000152	0.00526	CbGpPWpGaD
Gliclazide—Gastrointestinal pain—Docetaxel—skin cancer	0.000151	0.000495	CcSEcCtD
Gliclazide—Abdominal pain—Docetaxel—skin cancer	0.000146	0.000479	CcSEcCtD
Gliclazide—Body temperature increased—Docetaxel—skin cancer	0.000146	0.000479	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—IL6—skin cancer	0.000145	0.00503	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—TP53—skin cancer	0.000145	0.00502	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000144	0.00498	CbGpPWpGaD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000141	0.00488	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—HRAS—skin cancer	0.000138	0.0048	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—RASA1—skin cancer	0.000137	0.00475	CbGpPWpGaD
Gliclazide—Hypersensitivity—Docetaxel—skin cancer	0.000136	0.000446	CcSEcCtD
Gliclazide—Asthenia—Docetaxel—skin cancer	0.000132	0.000434	CcSEcCtD
Gliclazide—Pruritus—Docetaxel—skin cancer	0.000131	0.000428	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—BRAF—skin cancer	0.000128	0.00443	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—NRAS—skin cancer	0.000127	0.0044	CbGpPWpGaD
Gliclazide—Diarrhoea—Docetaxel—skin cancer	0.000126	0.000414	CcSEcCtD
Gliclazide—Dizziness—Docetaxel—skin cancer	0.000122	0.0004	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—NRAS—skin cancer	0.00012	0.00416	CbGpPWpGaD
Gliclazide—Vomiting—Docetaxel—skin cancer	0.000117	0.000385	CcSEcCtD
Gliclazide—Rash—Docetaxel—skin cancer	0.000116	0.000382	CcSEcCtD
Gliclazide—Dermatitis—Docetaxel—skin cancer	0.000116	0.000381	CcSEcCtD
Gliclazide—Headache—Docetaxel—skin cancer	0.000116	0.000379	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—CDK4—skin cancer	0.000111	0.00385	CbGpPWpGaD
Gliclazide—Nausea—Docetaxel—skin cancer	0.00011	0.00036	CcSEcCtD
Gliclazide—ABCC8—Metabolism—PLIN2—skin cancer	0.000109	0.0038	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—KRAS—skin cancer	0.000109	0.00379	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PLIN2—skin cancer	0.000106	0.00368	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—KRAS—skin cancer	0.000103	0.00358	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—HRAS—skin cancer	0.000103	0.00357	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—BRAF—skin cancer	0.000103	0.00356	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000103	0.00356	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—BRAF—skin cancer	9.96e-05	0.00346	CbGpPWpGaD
Gliclazide—CYP2C19—Arachidonic acid metabolism—PTGS2—skin cancer	9.5e-05	0.0033	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	9.29e-05	0.00322	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTCH2—skin cancer	8.89e-05	0.00309	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—IL6—skin cancer	8.89e-05	0.00308	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CSPG4—skin cancer	8.82e-05	0.00306	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—HRAS—skin cancer	8.77e-05	0.00304	CbGpPWpGaD
Gliclazide—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	8.66e-05	0.00301	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CSPG4—skin cancer	8.56e-05	0.00297	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—CDKN2A—skin cancer	8.47e-05	0.00294	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—IL6—skin cancer	8.39e-05	0.00291	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—KRAS—skin cancer	8.29e-05	0.00288	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	7.93e-05	0.00275	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TP53—skin cancer	7.37e-05	0.00256	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC12A2—skin cancer	7.14e-05	0.00248	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	7.11e-05	0.00247	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	6.87e-05	0.00238	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GLI2—skin cancer	6.74e-05	0.00234	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—PTGS2—skin cancer	6.73e-05	0.00234	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CDK4—skin cancer	6.71e-05	0.00233	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL6—skin cancer	6.57e-05	0.00228	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	6.49e-05	0.00225	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MC1R—skin cancer	6.43e-05	0.00223	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GLI1—skin cancer	6.34e-05	0.0022	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	6.11e-05	0.00212	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SUFU—skin cancer	6.01e-05	0.00208	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ENO2—skin cancer	6e-05	0.00208	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—HRAS—skin cancer	5.87e-05	0.00204	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ENO2—skin cancer	5.82e-05	0.00202	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—IL6—skin cancer	5.67e-05	0.00197	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—NRAS—skin cancer	5.23e-05	0.00182	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TP53—skin cancer	5.04e-05	0.00175	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—HRAS—skin cancer	4.72e-05	0.00164	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—TP53—skin cancer	4.72e-05	0.00164	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL6—skin cancer	4.62e-05	0.0016	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SHH—skin cancer	4.58e-05	0.00159	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—HRAS—skin cancer	4.58e-05	0.00159	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RASA1—skin cancer	4.55e-05	0.00158	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—KRAS—skin cancer	4.5e-05	0.00156	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTCH1—skin cancer	4.34e-05	0.00151	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SMO—skin cancer	4.34e-05	0.00151	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—IL6—skin cancer	4.32e-05	0.0015	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTGER4—skin cancer	4.23e-05	0.00147	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—HRAS—skin cancer	3.83e-05	0.00133	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FOXO4—skin cancer	3.74e-05	0.0013	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—NRAS—skin cancer	3.73e-05	0.0013	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IL6—skin cancer	3.67e-05	0.00127	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—IL6—skin cancer	3.66e-05	0.00127	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—NRAS—skin cancer	3.66e-05	0.00127	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PLIN2—skin cancer	3.53e-05	0.00122	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ERCC2—skin cancer	3.48e-05	0.00121	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ERCC2—skin cancer	3.38e-05	0.00117	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—KRAS—skin cancer	3.21e-05	0.00111	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PLIN2—skin cancer	3.17e-05	0.0011	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—KRAS—skin cancer	3.15e-05	0.00109	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PLIN2—skin cancer	2.89e-05	0.001	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CSPG4—skin cancer	2.85e-05	0.000987	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—skin cancer	2.8e-05	0.000972	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—HRAS—skin cancer	2.73e-05	0.000948	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—HRAS—skin cancer	2.68e-05	0.00093	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—IL6—skin cancer	2.61e-05	0.000907	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CSPG4—skin cancer	2.55e-05	0.000886	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TERT—skin cancer	2.49e-05	0.000866	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CSPG4—skin cancer	2.33e-05	0.000808	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—skin cancer	2.09e-05	0.000725	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—skin cancer	2.03e-05	0.000703	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—BRAF—skin cancer	1.98e-05	0.000685	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ENO2—skin cancer	1.93e-05	0.000671	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ENO2—skin cancer	1.74e-05	0.000602	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ENO2—skin cancer	1.58e-05	0.000549	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.51e-05	0.000525	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.36e-05	0.000471	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NRAS—skin cancer	1.29e-05	0.000448	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NRAS—skin cancer	1.24e-05	0.000431	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.24e-05	0.000429	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ERCC2—skin cancer	1.12e-05	0.00039	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—skin cancer	1.11e-05	0.000386	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—skin cancer	1.07e-05	0.000371	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ERCC2—skin cancer	1.01e-05	0.00035	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—skin cancer	9.89e-06	0.000343	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—skin cancer	9.5e-06	0.00033	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—skin cancer	9.46e-06	0.000328	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ERCC2—skin cancer	9.19e-06	0.000319	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—skin cancer	9.08e-06	0.000315	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—skin cancer	8.69e-06	0.000302	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—skin cancer	6.74e-06	0.000234	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—skin cancer	6.05e-06	0.00021	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—skin cancer	5.51e-06	0.000191	CbGpPWpGaD
